Arbutus Biopharma Corporation

Historical 13F Holders

Symbol
ABUS
CUSIP
03879J100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03879J100 since 12/18/2024, newest first.

Filer % of Class Filed
Morgan Stanley 13G/A Amendment 4
12.2% 10/7/2026
Event 9/30/2026
Roivant Sciences Ltd. 13D/A Amendment 14 19.5% 10/5/2026
Event 10/1/2026
Whitefort Capital Management, LP 13G
8.0% 9/4/2026
Event 9/4/2026
Morgan Stanley 13G/A Amendment 3
8.8% 8/12/2026
Event 6/30/2026
Two Seas Capital LP 13G/A Amendment 2
9.4% 5/15/2026
Event 3/31/2026
Whitefort Capital Management, LP 13D/A Amendment 4
8.0% 4/28/2026
Event 4/24/2026
Whitefort Capital Management, LP 13D/A Amendment 3
8.1% 4/13/2026
Event 4/10/2026
Two Seas Capital LP 13G/A Amendment 1
6.5% 2/17/2026
Event 12/31/2025
Morgan Stanley 13G/A Amendment 2
13.5% 2/11/2026
Event 12/31/2025
Two Seas Capital LP 13G
5.4% 8/13/2025
Event 6/30/2025
Roivant Sciences Ltd. 13D/A Amendment 13 20.5% 2/25/2025
Event 2/21/2025
Whitefort Capital Management, LP 13D/A Amendment 2
7.0% 2/21/2025
Event 2/20/2025
Roivant Sciences Ltd. 13D/A Amendment 12 20.5% 2/18/2025
Event 2/18/2025
Morgan Stanley 13G/A Amendment 1
11.4% 2/3/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 8.43 M $40.3 M
2026 Q2 182 142 M $861 M
2026 Q1 179 139 M $626 M
2025 Q4 192 122 M $587 M
2025 Q3 185 118 M $537 M
2025 Q2 178 118 M $366 M
2025 Q1 187 112 M $390 M
2024 Q4 167 104 M $340 M
2024 Q3 157 101 M $390 M
2024 Q2 142 118 M $363 M
2024 Q1 136 101 M $261 M
2023 Q4 130 86.2 M $215 M
2023 Q3 110 74.9 M $152 M
2023 Q2 121 66.2 M $152 M
2023 Q1 136 65.1 M $197 M
2022 Q4 129 56.3 M $131 M
2022 Q3 144 46.7 M $89.2 M
2022 Q2 126 44.3 M $120 M
2022 Q1 137 43.9 M $131 M
2021 Q4 149 40.5 M $157 M
2021 Q3 122 34.9 M $150 M
2021 Q2 104 28.9 M $87.6 M
2021 Q1 107 26.0 M $86.5 M
2020 Q4 97 23.4 M $83.4 M
2020 Q3 79 24.1 M $75.5 M
2020 Q2 55 26.1 M $47.6 M
2020 Q1 53 26.3 M $26.5 M
2019 Q4 64 24.4 M $67.8 M
2019 Q3 57 19.5 M $29.7 M
2019 Q2 72 21.2 M $44.1 M
2019 Q1 77 24.1 M $86.5 M
2018 Q4 82 24.4 M $93.5 M
2018 Q3 100 24.7 M $234 M
2018 Q2 79 22.3 M $159 M
2018 Q1 58 18.4 M $92.2 M
2017 Q4 54 34.2 M $173 M
2017 Q3 58 33.0 M $207 M
2017 Q2 53 36.9 M $133 M
2017 Q1 58 36.6 M $119 M
2016 Q4 63 36.5 M $89.5 M
2016 Q3 55 33.4 M $115 M
2016 Q2 57 17.6 M $61.1 M
2016 Q1 56 17.7 M $73.1 M
2015 Q4 57 18.4 M $81.7 M
2015 Q3 59 34.9 M $212 M
2015 Q2 1 207 k $2.46 M